+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Head and Neck Squamous Cell Carcinoma - Global Drug Forecast and Market Analysis to 2030

  • ID: 5464463
  • Report
  • October 2021
  • Region: Global
  • 131 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Head and neck squamous cell carcinoma (HNSCC) was the sixth most common cancer type by worldwide incidence in 2020. However, until recently, there had been limited research and development in HNSCC, resulting in a market with little competition and a stagnant pipeline. Historically, cytotoxic chemotherapies have made up the majority of the HNSCC market. There is currently little competition between targeted therapies in the HNSCC market, leaving an area of considerable opportunity for interested newcomers. Despite the approvals of PD-1 inhibitors, which have changed the treatment for platinum (Pt)-refractory HNSCC patients, cisplatin-based chemotherapy still remains the standard treatment for locally advanced (LA) HNSCC and newly diagnosed recurrent/metastatic (R/M) HNSCC.

The approval of Eli Lilly’s Erbitux in 2006 introduced the only non-chemotherapy agent available to HNC patients until 2016. In 2016, immunotherapies entered the HNSCC space with the approval of Merck & Co.'s Keytruda and BMS' Opdivo as treatments for R/M HNSCC, followed by Keytruda’s expansion into first-line setting for PD-L1 positive and all-comer patients. During 2020-2030, the competitive landscape will continue to evolve with the label extension of Keytruda as an adjuvant treatment for LA-HNC patients, and the launch of 11 pipeline agents. Among these, six belong to the ICI class, which, as a class, are expected to be the main driver of market growth. As a result of this active level of clinical development, specifically with immunotherapies, the HNSCC market is expected to grow dramatically across the 8MM.

This report covers opportunities for various marketed agents and pipeline agents in development across the 8MM, clinical and commercial assessments for agents in late-stage clinical development, R&D strategies, and innovative approaches in development for HNSCC breast cancer. This edition provides an update to the previous sales forecast for marketed and pipeline agents and highlights expected market dynamics by country and class of therapy across the forecast period, 2020-2030.

Key Highlights


  • The main drivers of growth include the anticipated label expansion of currently marketed therapies and the approval and launch of 11 pipeline therapies and greater market access across the 8MM for premium priced agents.
  • The main barriers to growth in the 8MM are the patent expiries of the leading brands across the 8MM.
  • The most important unmet needs in the HNSCC market include: Efficacious treatments for patients via personalization of therapy and identification of druggable targets.

KEY QUESTIONS ANSWERED

  • 11 late-stage pipeline agents are going to enter the HNSCC market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in HNSCC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope


  • Overview of HNSCC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline HNSCC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HNSCC therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global HNSCC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy


The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global HNSCC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNSCC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HNSCC therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
1 Head and Neck Squamous Cell Carcinoma: Executive Summary
1.1 The Head and Neck Squamous Cell Carcinoma Market Will Grow to $5.2B in 2030
1.2 Merck & Co. Expected to Maintain Its Market-Leading Position
1.3 Extending Overall Survival Remains a Major Unmet Need
1.4 Immune Checkpoint Inhibitors Expected to Launch in Locally Advanced and Recurrent/Metastatic Settings
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.5 Epidemiological Forecast for HNC (2020-2030)
4.6 Discussion

5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Key Opinion Leader Insights on Disease Management

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Urban China
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix

List of Tables
Table 1: Head and Neck Squamous Cell Carcinoma: Key Metrics in the 8MM
Table 2: ICD-10 Codes Used to Classify HNC
Table 3: TNM Classification of Cancers of the Oral Cavity (Including Mucosa of the Lip)
Table 4: TNM Classification of Cancers of the Oropharynx (p16-) and Hypopharynx
Table 5: TNM Classification of Cancers of the Oropharynx - HPV Mediated (p16+)
Table 6: TNM Classification of Cancers of the Larynx
Table 7: TNM Classification of Cancers of the Nasal Cavity and Paranasal Sinuses
Table 8: TNM Classification of Cancers of the Nasopharynx
Table 9: Stage Grouping for Cancers of the Oral Cavity (Including Mucosa of the Lip)
Table 10: Stage Grouping for Cancers of the Larynx
Table 11: Stage Grouping for Cancers of the Oropharynx (p16+)
Table 12: Stage Grouping for Cancers of the Oropharynx (p16-) and Hypopharynx
Table 13: Stage Grouping for Cancers of the Nasopharynx
Table 14: Risk Factors and Comorbid Conditions Associated with HNCs
Figure 15: 8MM, Diagnosed Incidence of HNC, Men and Women (Cases per 100,000 Population), Ages ≥18 Years, 2020
Table 16: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2020
Table 17: 8MM, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2020
Table 18: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2020
Table 19: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factor, Histology Distribution, and Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2020
Table 20: Treatment Guidelines for HNSCC Across the 8MM
Table 21: Top 10 Deals by Value, 2018-2020
Table 22: HNSCC Market - Global Drivers and Barriers, 2020-2030
Table 23: Key Events Impacting Sales for HNSCC in the US, 2020-2030
Table 24: HNSCC Market - Drivers and Barriers in the US, 2020-2030
Table 25: Key Events Impacting Sales for HNSCC in the 5EU, 2020-2030
Table 26: HNSCC Market - Drivers and Barriers in the 5EU, 2020-2030
Table 27: Key Events Impacting Sales for HNSCC in Japan, 2020-2030
Table 28: HNSCC Market - Drivers and Barriers in Japan, 2020-2030
Table 29: Key Events Impacting Sales for HNSCC in Urban China, 2020-2030
Table 30: HNSCC Market - Drivers and Barriers in Urban China, 2020-2030
Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for HNSCC in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in HNSCC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the Analyst Expects to Be Licensed for the Treatment of HNSCC During the Forecast Period in the Locally Advanced Setting
Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that the Analyst Expects to Be Licensed for the Treatment of HNSCC During the Forecast Period in the Recurrent/Metastatic Setting
Figure 5: Common Anatomical Sites of HNSCC
Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])
Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10); Nasopharynx Cancer (ICD-10 = C11); Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 8: 8MM, Sources Used, Five-Year Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 9: 8MM, Sources Used to Forecast the Risk Factors and Histology Distribution Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]), Oropharynx Cancer (ICD-10 = C10), Nasopharynx Cancer (ICD-10 = C11), Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)
Figure 10: 8MM, Sources Used to Forecast the Stage at Diagnosis Among Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Oropharynx Cancer, Nasopharynx Cancer, and Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
Figure 11: 8MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 13: 8MM, Diagnosed Incident Cases of Oropharynx Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 15: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Age, N, Both Sexes, 2020
Figure 16: 8MM, Diagnosed Incident Cases of Nasopharynx Cancer by Sex, N, Ages ≥18 Years, 2020
Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 18: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 19: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Age, N, Both Sexes, 2020
Figure 20: 8MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Sex, N, Ages ≥18 Years, 2020
Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, N, Both Sexes, Ages ≥18 Years, 2020
Figure 22: Treatment Algorithm in HNSCC: Oral Cavity (Including Mucosa of the Lip), Pharynx, Larynx, Salivary Glands, and Paranasal Sinuses
Figure 23: Treatment Algorithm in HNSCC: Nasopharynx
Figure 24: Unmet Needs and Opportunities in HNSCC
Figure 25: Overview of the Development Pipeline in HNSCC
Figure 26: Key Late-Stage Trials for the Promising Pipeline Agents that the Analyst Expects to Be Licensed for HNSCC in the 8MM During the Forecast Period
Figure 27: Competitive Assessment of Key Pipeline Products - LA-HNSCC
Figure 28: Competitive Assessment of Key Pipeline Products - R/M-HNSCC
Figure 29: Analysis of the Company Portfolio Gap in HNSCC During the Forecast Period
Figure 30: Global (8MM) Sales Forecast by Country for HNSCC in 2020 and 2030
Figure 31: Sales Forecast by Class for HNSCC in the US in 2020 and 2030
Figure 32: Sales Forecast by Class for HNSCC in the 5EU in 2020 and 2030
Figure 33: Sales Forecast by Class for HNSCC in Japan in 2020 and 2030
Figure 34: Sales Forecast by Class for HNSCC in Urban China in 2020 and 2030
Note: Product cover images may vary from those shown